Medical - Healthcare Information Services
Compare Stocks
4 / 10Stock Comparison
NUTX vs ADUS vs SGRY vs HCSG
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Care Facilities
Medical - Care Facilities
Medical - Care Facilities
NUTX vs ADUS vs SGRY vs HCSG — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||||
|---|---|---|---|---|
| Industry | Medical - Healthcare Information Services | Medical - Care Facilities | Medical - Care Facilities | Medical - Care Facilities |
| Market Cap | $801M | $1.81B | $1.87B | $1.60B |
| Revenue (TTM) | $880M | $1.45B | $3.34B | $1.84B |
| Net Income (TTM) | $96M | $100M | $-76M | $59M |
| Gross Margin | 47.5% | 32.5% | 22.8% | 13.3% |
| Operating Margin | 31.4% | 9.8% | 11.8% | 3.0% |
| Forward P/E | 8.7x | 14.1x | 38.0x | 20.8x |
| Total Debt | $351M | $209M | $4.02B | $25M |
| Cash & Equiv. | $186M | $82M | $240M | $161M |
NUTX vs ADUS vs SGRY vs HCSG — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Apr 22 | May 26 | Return |
|---|---|---|---|
| Nutex Health, Inc. (NUTX) | 100 | 9.5 | -90.5% |
| Addus HomeCare Corp… (ADUS) | 100 | 115.4 | +15.4% |
| Surgery Partners, I… (SGRY) | 100 | 28.0 | -72.0% |
| Healthcare Services… (HCSG) | 100 | 130.5 | +30.5% |
Price return only. Dividends and distributions are not included.
Quick Verdict: NUTX vs ADUS vs SGRY vs HCSG
Each card shows where this stock fits in a portfolio — not just who wins on paper.
NUTX carries the broadest edge in this set and is the clearest fit for growth exposure.
- Rev growth 82.4%, EPS growth 7.9%, 3Y rev CAGR 58.6%
- 82.4% revenue growth vs SGRY's 6.2%
- Lower P/E (8.7x vs 20.8x)
- 11.0% margin vs SGRY's -2.3%
ADUS is the #2 pick in this set and the best alternative if income & stability and long-term compounding is your priority.
- Dividend streak 2 yrs, beta 0.58
- 399.9% 10Y total return vs SGRY's -0.6%
- Lower volatility, beta 0.58, Low D/E 19.2%, current ratio 1.80x
- Beta 0.58, current ratio 1.80x
SGRY lags the leaders in this set but could rank higher in a more targeted comparison.
HCSG is the clearest fit if your priority is momentum.
- +55.8% vs SGRY's -38.2%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 82.4% revenue growth vs SGRY's 6.2% | |
| Value | Lower P/E (8.7x vs 20.8x) | |
| Quality / Margins | 11.0% margin vs SGRY's -2.3% | |
| Stability / Safety | Beta 0.58 vs NUTX's 2.01, lower leverage | |
| Dividends | Tie | None of these 4 stocks pay a meaningful dividend |
| Momentum (1Y) | +55.8% vs SGRY's -38.2% | |
| Efficiency (ROA) | 10.5% ROA vs SGRY's -0.9%, ROIC 38.0% vs 4.1% |
NUTX vs ADUS vs SGRY vs HCSG — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
NUTX vs ADUS vs SGRY vs HCSG — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
NUTX leads in 1 of 6 categories
HCSG leads 1 • ADUS leads 0 • SGRY leads 0 • 4 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
NUTX leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
SGRY is the larger business by revenue, generating $3.3B annually — 3.8x NUTX's $880M. NUTX is the more profitable business, keeping 11.0% of every revenue dollar as net income compared to SGRY's -2.3%. On growth, ADUS holds the edge at +7.7% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||||
|---|---|---|---|---|
| RevenueTrailing 12 months | $880M | $1.4B | $3.3B | $1.8B |
| EBITDAEarnings before interest/tax | $297M | $159M | $572M | $72M |
| Net IncomeAfter-tax profit | $96M | $100M | -$76M | $59M |
| Free Cash FlowCash after capex | $270M | $137M | $208M | $139M |
| Gross MarginGross profit ÷ Revenue | +47.5% | +32.5% | +22.8% | +13.3% |
| Operating MarginEBIT ÷ Revenue | +31.4% | +9.8% | +11.8% | +3.0% |
| Net MarginNet income ÷ Revenue | +11.0% | +6.9% | -2.3% | +3.2% |
| FCF MarginFCF ÷ Revenue | +30.7% | +9.5% | +6.2% | +7.6% |
| Rev. Growth (YoY)Latest quarter vs prior year | +2.2% | +7.7% | +4.5% | +6.6% |
| EPS Growth (YoY)Latest quarter vs prior year | +154.7% | +17.2% | +6.7% | +175.0% |
Valuation Metrics
Evenly matched — NUTX and SGRY each lead in 3 of 6 comparable metrics.
Valuation Metrics
At 12.8x trailing earnings, NUTX trades at a 53% valuation discount to HCSG's 27.5x P/E. On an enterprise value basis, NUTX's 3.3x EV/EBITDA is more attractive than HCSG's 22.4x.
| Metric | ||||
|---|---|---|---|---|
| Market CapShares × price | $801M | $1.8B | $1.9B | $1.6B |
| Enterprise ValueMkt cap + debt − cash | $967M | $1.9B | $5.7B | $1.5B |
| Trailing P/EPrice ÷ TTM EPS | 12.84x | 18.67x | -23.46x | 27.54x |
| Forward P/EPrice ÷ next-FY EPS est. | 8.73x | 14.12x | 37.99x | 20.83x |
| PEG RatioP/E ÷ EPS growth rate | — | 0.93x | — | — |
| EV / EBITDAEnterprise value multiple | 3.27x | 12.52x | 10.00x | 22.38x |
| Price / SalesMarket cap ÷ Revenue | 0.92x | 1.28x | 0.57x | 0.87x |
| Price / BookPrice ÷ Book value/share | 2.15x | 1.65x | 0.52x | 3.19x |
| Price / FCFMarket cap ÷ FCF | 3.26x | 17.48x | 9.57x | 11.49x |
Profitability & Efficiency
Evenly matched — NUTX and HCSG each lead in 5 of 9 comparable metrics.
Profitability & Efficiency
NUTX delivers a 22.2% return on equity — every $100 of shareholder capital generates $22 in annual profit, vs $-2 for SGRY. HCSG carries lower financial leverage with a 0.05x debt-to-equity ratio, signaling a more conservative balance sheet compared to SGRY's 1.14x. On the Piotroski fundamental quality scale (0–9), NUTX scores 7/9 vs SGRY's 5/9, reflecting strong financial health.
| Metric | ||||
|---|---|---|---|---|
| ROE (TTM)Return on equity | +22.2% | +9.3% | -2.2% | +11.8% |
| ROA (TTM)Return on assets | +10.5% | +7.0% | -0.9% | +7.3% |
| ROICReturn on invested capital | +38.0% | +8.8% | +4.1% | +9.0% |
| ROCEReturn on capital employed | +43.2% | +10.9% | +5.2% | +7.7% |
| Piotroski ScoreFundamental quality 0–9 | 7 | 7 | 5 | 7 |
| Debt / EquityFinancial leverage | 0.83x | 0.19x | 1.14x | 0.05x |
| Net DebtTotal debt minus cash | $166M | $127M | $3.8B | -$136M |
| Cash & Equiv.Liquid assets | $186M | $82M | $240M | $161M |
| Total DebtShort + long-term debt | $351M | $209M | $4.0B | $25M |
| Interest CoverageEBIT ÷ Interest expense | 9.13x | 14.45x | 1.35x | 33.02x |
Total Returns (Dividends Reinvested)
Evenly matched — NUTX and ADUS and HCSG each lead in 2 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ADUS five years ago would be worth $10,002 today (with dividends reinvested), compared to $224 for NUTX. Over the past 12 months, HCSG leads with a +55.8% total return vs SGRY's -38.2%. The 3-year compound annual growth rate (CAGR) favors NUTX at 20.5% vs SGRY's -25.8% — a key indicator of consistent wealth creation.
| Metric | ||||
|---|---|---|---|---|
| YTD ReturnYear-to-date | -9.2% | -8.7% | -6.2% | +28.6% |
| 1-Year ReturnPast 12 months | +14.6% | -13.4% | -38.2% | +55.8% |
| 3-Year ReturnCumulative with dividends | +74.8% | +16.3% | -59.2% | +48.6% |
| 5-Year ReturnCumulative with dividends | -97.8% | +0.0% | -72.3% | -21.1% |
| 10-Year ReturnCumulative with dividends | -97.8% | +399.9% | -0.6% | -26.8% |
| CAGR (3Y)Annualised 3-year return | +20.5% | +5.2% | -25.8% | +14.1% |
Risk & Volatility
Evenly matched — ADUS and HCSG each lead in 1 of 2 comparable metrics.
Risk & Volatility
ADUS is the less volatile stock with a 0.58 beta — it tends to amplify market swings less than NUTX's 2.01 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. HCSG currently trades 91.5% from its 52-week high vs SGRY's 59.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||||
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 2.01x | 0.58x | 1.04x | 1.12x |
| 52-Week HighHighest price in past year | $193.07 | $124.44 | $24.18 | $24.39 |
| 52-Week LowLowest price in past year | $77.21 | $90.89 | $11.41 | $12.66 |
| % of 52W HighCurrent price vs 52-week peak | +69.7% | +78.2% | +59.2% | +91.5% |
| RSI (14)Momentum oscillator 0–100 | 59.7 | 49.3 | 63.3 | 61.8 |
| Avg Volume (50D)Average daily shares traded | 197K | 236K | 1.5M | 676K |
Analyst Outlook
HCSG leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
Analyst consensus: NUTX as "Buy", ADUS as "Buy", SGRY as "Buy", HCSG as "Hold". Consensus price targets imply 52.3% upside for NUTX (target: $205) vs 9.8% for HCSG (target: $25).
| Metric | ||||
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy | Hold |
| Price TargetConsensus 12-month target | $205.00 | $128.67 | $18.60 | $24.50 |
| # AnalystsCovering analysts | 2 | 15 | 22 | 15 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — |
| Dividend StreakConsecutive years of raises | 1 | 2 | 0 | 20 |
| Dividend / ShareAnnual DPS | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | +0.6% | 0.0% | 0.0% | +3.9% |
NUTX leads in 1 of 6 categories (Income & Cash Flow). HCSG leads in 1 (Analyst Outlook). 4 tied.
NUTX vs ADUS vs SGRY vs HCSG: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is NUTX or ADUS or SGRY or HCSG a better buy right now?
For growth investors, Nutex Health, Inc.
(NUTX) is the stronger pick with 82. 4% revenue growth year-over-year, versus 6. 2% for Surgery Partners, Inc. (SGRY). Nutex Health, Inc. (NUTX) offers the better valuation at 12. 8x trailing P/E (8. 7x forward), making it the more compelling value choice. Analysts rate Nutex Health, Inc. (NUTX) a "Buy" — based on 2 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — NUTX or ADUS or SGRY or HCSG?
On trailing P/E, Nutex Health, Inc.
(NUTX) is the cheapest at 12. 8x versus Healthcare Services Group, Inc. at 27. 5x. On forward P/E, Nutex Health, Inc. is actually cheaper at 8. 7x.
03Which is the better long-term investment — NUTX or ADUS or SGRY or HCSG?
Over the past 5 years, Addus HomeCare Corporation (ADUS) delivered a total return of +0.
0%, compared to -97. 8% for Nutex Health, Inc. (NUTX). Over 10 years, the gap is even starker: ADUS returned +399. 9% versus NUTX's -97. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — NUTX or ADUS or SGRY or HCSG?
By beta (market sensitivity over 5 years), Addus HomeCare Corporation (ADUS) is the lower-risk stock at 0.
58β versus Nutex Health, Inc. 's 2. 01β — meaning NUTX is approximately 250% more volatile than ADUS relative to the S&P 500. On balance sheet safety, Healthcare Services Group, Inc. (HCSG) carries a lower debt/equity ratio of 5% versus 114% for Surgery Partners, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — NUTX or ADUS or SGRY or HCSG?
By revenue growth (latest reported year), Nutex Health, Inc.
(NUTX) is pulling ahead at 82. 4% versus 6. 2% for Surgery Partners, Inc. (SGRY). On earnings-per-share growth, the picture is similar: Surgery Partners, Inc. grew EPS 54. 1% year-over-year, compared to 7. 9% for Nutex Health, Inc.. Over a 3-year CAGR, NUTX leads at 58. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — NUTX or ADUS or SGRY or HCSG?
Nutex Health, Inc.
(NUTX) is the more profitable company, earning 8. 1% net margin versus -2. 4% for Surgery Partners, Inc. — meaning it keeps 8. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NUTX leads at 31. 5% versus 2. 6% for HCSG. At the gross margin level — before operating expenses — NUTX leads at 50. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is NUTX or ADUS or SGRY or HCSG more undervalued right now?
On forward earnings alone, Nutex Health, Inc.
(NUTX) trades at 8. 7x forward P/E versus 38. 0x for Surgery Partners, Inc. — 29. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for NUTX: 52. 3% to $205. 00.
08Which pays a better dividend — NUTX or ADUS or SGRY or HCSG?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
09Is NUTX or ADUS or SGRY or HCSG better for a retirement portfolio?
For long-horizon retirement investors, Addus HomeCare Corporation (ADUS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
58), +399. 9% 10Y return). Nutex Health, Inc. (NUTX) carries a higher beta of 2. 01 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ADUS: +399. 9%, NUTX: -97. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between NUTX and ADUS and SGRY and HCSG?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: NUTX is a small-cap high-growth stock; ADUS is a small-cap high-growth stock; SGRY is a small-cap quality compounder stock; HCSG is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.